Anti-idiotype cancer vaccine 1A7 - Titan

Drug Profile

Anti-idiotype cancer vaccine 1A7 - Titan

Alternative Names: 1A7; anti-Id antibody 1A7; GD2 anti-idiotype cancer vaccine - Titan; TriGem

Latest Information Update: 26 Aug 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Titan Pharmaceuticals
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malignant melanoma; Neuroblastoma

Most Recent Events

  • 26 Aug 2004 Discontinued - Phase-I for Neuroblastoma in USA (unspecified route)
  • 26 Aug 2004 Discontinued - Phase-II for Malignant melanoma in USA (SC)
  • 23 Jul 2002 A study has been added to the adverse events and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top